Login:
 
Lockyer M. Comparing cardiovascular outcomes in different diabetes drug classes. Practitioner March 2018;262(1813):8

Comparing cardiovascular outcomes in different diabetes drug classes

22 Mar 2018Registered users

Canagliflozin was associated with a lower risk of heart failure admissions compared with other classes of diabetes drugs, in a population-based retrospective cohort study from the United States.

Registered usersThis article can only be accessed if you are a registered user of thepractitioner.co.uk or a subscriber to The Practitioner.

To buy this article (£25+tax) copy the article citation above and click Buy article